Loading…
Loading…
AMPE does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for AMPE and 80,000+ other tickers.
See exactly how AMPE's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for AMPE and 80,000+ other tickers.
Ampio Pharmaceuticals, Inc., headquartered in Englewood, Colorado, is a biopharmaceutical firm dedicated to advancing immunomodulatory therapeutics primarily for the management of osteoarthritis pain across the United States. Their developmental pipeline currently features several compounds: AP-013, an intra-articular injection, is undergoing Phase III clinical trials for knee osteoarthritis. Additionally, the company has multiple candidates addressing COVID-19: AP-017, an intravenous Ampion formulation, is in Phase II for adult COVID-19 patients who require supplemental oxygen; AP-019, an…
Institutional and Insider Ownership 44.0% of Vincerx Pharma shares are held by institutional investors. Comparatively, 5.7% of Ampio Pharmaceuticals shares are held by institutional investors. 15.6% of Vincerx Pharma shares are held by insiders. Comparatively, 3.3% of Ampio Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments
Profitability This table compares Trevena and Ampio Pharmaceuticals' net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Trevena N/A N/A -119.55% Ampio Pharmaceuticals N/A N/A N/A Earnings and Valuation This table compares Trevena and Ampio Pharmaceuticals"s top-line revenue, earnings per share and valuation. Gross Revenue Price/Sales Ratio
Volatility and Risk Graybug Vision has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500. Comparatively, Ampio Pharmaceuticals has a beta of 5.57, indicating that its share price is 457% more volatile than the S&P 500. Valuation and Earnings This table compares Graybug Vision and Ampio Pharmaceuticals"s
ENGLEWOOD, Colo., April 3, 2024 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company" or "Ampio") today announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2023, which was filed on March 27, 2024 with the Securities and Exchange Commission, the audited financial statements contained an unqualified audit opinion from its independent registered public accounting firm that included an explanatory paragraph related to the Company's ability to continue as a going concern.
ENGLEWOOD, Colo. , March 25, 2024 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company" or "Ampio") today announced that its Board of Directors determined to voluntarily delist its common stock from the NYSE American and deregister its common stock in order to terminate and suspend its reporting obligations under the Securities and Exchange Act of 1934, as amended (the "Exchange Act").